HelioLiver LDT now available to order through Quest Diagnostics
Helio Genomics Our Story Technology Research Our Team Blog & Interviews News & Media HelioLiver LDT Overview The Science For Providers The HelioLiver Test Clinical Evidence FAQ For Patients Overview Early Detection Testing with HelioLiver The HelioLiver Test FAQ Contact
Modern corporate skyline
Helio Genomics · Newsroom

Investor Relations

Recent press coverage and publications have highlighted Helio Genomics' market momentum in early cancer detection and diagnostics innovation.

Featured Coverage

Business Insider67.7M Monthly Visitors

Helio Genomics Announces New HelioLiver Access Through Quest

Business Insider covers the expanded provider access for HelioLiver beginning April 2026, detailing how healthcare providers with existing Quest accounts can order the blood-based liver cancer test through Quest's infrastructure of approximately 7,700 patient service centers and EHR integration.

Read the Coverage

In the Press

Helio Genomics' science, commercial milestones, and the Quest Diagnostics partnership have been covered across leading financial, industry, and clinical media.

Orange County Business Journal coverageNews
Orange County Business Journal61.2K UVM

Helio Genomics Enters Full Launch with Quest Diagnostics

Read on
Yahoo! News coverageNews
Yahoo! News44.5M UVM

Improving Early Detection and Treatment of Liver Cancer

Read on
FinanceWire coverageNews
FinanceWire102.2K UVM

Helio Genomics Announces New HelioLiver Access Through Quest

Read on
GlobalData coverageNews
GlobalData307.1K UVM

Improving Early Detection and Treatment of Liver Cancer

Read on
Dealroom.co coverageNews
Dealroom.co33K UVM

Quest Diagnostics to Offer Helio Genomics' AI-Powered Liver Cancer Blood Test Across US Network

Read on
Precision Medicine Online coverageNews
Precision Medicine Online156K UVM

Helio Genomics Mulls New AI-Driven Dx Opportunities While Readying Liver Cancer Test for US

Read on
Simply Wall St. News coverageNews
Simply Wall St. News2.5M UVM

How Investors May Respond to Quest Diagnostics (DGX) Expanding Blood-Based Cancer Screening and Boardroom Expertise

Read on
Scope Forward (Becker's GI & Endoscopy) coverageNews
Scope Forward (Becker's GI & Endoscopy)17.7K UVM

Quest Diagnostics to Offer Liver Cancer Blood Test

Read on
LiverRight coverageNews
LiverRight12.5K UVM

Helio Genomics and Quest Diagnostics

Read on
Becker's ASC Review coverageNews
Becker's ASC Review609K UVM

Quest Diagnostics to Offer Liver Cancer Blood Test

Read on
Brief Glance coverageNews
Brief Glance35K UVM

AI Blood Test for Liver Cancer Gains Massive Reach via Quest Deal

Read on
NewsBreak coverageNews
NewsBreak13.9M UVM

Quest Diagnostics to Offer Liver Cancer Blood Test

Read on
SAHM Capital coverageNews
SAHM Capital220.5K UVM

How Investors May Respond to Quest Diagnostics (DGX) Expanding Blood-Based Cancer Screening and Boardroom Expertise

Read on